Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1335, project P3, SFB824, project Z1, SFB824, project C3)
Charité – Universitätsmedizin Berlin
Received: 7 June 2021
Accepted: 7 August 2021
First Online: 21 August 2021
: Approval of the responsible ethics committees of University Hospital Würzburg and Klinikum rechts der Isar, was obtained for retrospective analysis of imaging and clinical data. All procedures were in accordance of the 1964 Declaration of Helsinki and its later amendments.
: All patients who participated in this study were informed prior to imaging about the intent of data publication. Written consent to participate in the imaging studies was obtained from all participants and can be made available to the editors on request.
: U.K. has served on the advisory board of PentixaPharm, the company that is developing clinical applications for Pentixafor and Pentixather. H.-J.W. is a founder, shareholder and advisory board member of Scintomics GmbH, Fürstenfeldbruck, Germany.